TNXP Stock Rises on Expanded Medicare Access for Fibromyalgia Drug TONMYA
Tonix secured expanded Medicare coverage for its fibromyalgia drug TONMYA, reaching approximately 9 million additional patients starting January 2027.
Tonix secured expanded Medicare coverage for its fibromyalgia drug TONMYA, reaching approximately 9 million additional patients starting January 2027.
The experimental treatment showed meaningful hair regrowth and a favorable safety profile.
The firm sees strong potential for zorevunersen in treating Dravet syndrome.
Strong outlook for ulixacaltamide and relutrigine approvals by early 2027.
Jefferies upgraded BeOne Medicines, citing strong Brukinsa growth, promising cancer drugs, and potential 27% stock upside.
The Florida-based surgical device maker faces margin pressures but sees strong interest from acquirers.